WANY
ACAD icon

Wealthspire Advisors (New York)’s Acadia Pharmaceuticals ACAD Stock Holding History

Wealthspire Advisors (New York)’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-124
Closed -$2.65K – 1044
2025
Q3 		$2.65K Buy
+124
New +$2.93K ﹤0.01% 2528
2019
Q1 		– Sell
-9,640
Closed -$156K – 53
2018
Q4 		$156K Buy
+9,640
New +$187K 0.02% 79

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Wealthspire Advisors (New York)'s ACAD Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Acadia Pharmaceuticals (ACAD) in Q4 2025, closing a stake of 124 shares — an estimated $2.65K sold.

Wealthspire Advisors (New York) first reported a position in ACAD in Q4 2018 and held it in 2 quarters. The position peaked at $156K in Q4 2018. 336 funds tracked by Wall St. Rank hold ACAD as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Acadia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 124 Acadia Pharmaceuticals shares in Q4 2025, an estimated $2.65K.
  • Wealthspire Advisors (New York) first reported a position in Acadia Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Wealthspire Advisors (New York)'s Acadia Pharmaceuticals position peaked at $156K in Q4 2018.
  • 336 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.